SEOM-TTCC clinical guideline in nasopharynx cancer (2021)
Clin. transl. oncol. (Print)
; 24(4): 670-680, abril 2022. ilus, tab
Article
in English
| IBECS
| ID: ibc-203771
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Therapeutics
/
Nasopharyngeal Neoplasms
/
Diagnosis
/
Nasopharyngeal Carcinoma
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2022
Document type:
Article
Institution/Affiliation country:
Catalan Institut of Oncology/Spain
/
Complejo Hospitalario Universitario de Ourense/Spain
/
Complejo Hospitalario de Navarra/Spain
/
Hospital Josep Trueta/Spain
/
Hospital Marqués de Valdecilla/Spain
/
Hospital Universitario Lucus Augusti/Spain
/
Hospital Universitario de La Paz/Spain
/
Hospital Virgen de La Salud/Spain
/
Regional and Virgen de La Victoria University Hospitals/Spain
